Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
11/2010
11/02/2010US7824695 recombinant proteins comprise cell recognition moiety that binds alpha 2 macroglobulin receptor, and bioactive moiety (pseudomonas exotoxin), which mediates systemic effect, does not function as immunogen and does not have ADP ribosylating activity
11/02/2010US7824688 Glucan-based vaccines
11/02/2010US7824684 Contain an Fc part derived from human origin and do not bind complement factor C1q; for inflammatory and thrombotic disorders such as critical limb ischemia or peripheral arterial occlusive disease; atherosclerosis, thrombosis, restenosis, asthma, arthritis
11/02/2010US7824683 Methods for augmenting an immune response using anti-CD40 antibodies
11/02/2010US7824682 Dna sequence and genomic structure of human cardiac isoform; gene or allele mutants associated with cardiovascular disorders; reduce stretch activation and adjust tension of muscles in heart contraction; isolated nucleic acid encoding a protein
11/02/2010US7824680 Methods for inhibiting angiogenesis
11/02/2010US7824679 Complementarity determining regions; immunoglobulins; cell line, host cells; transgenic animals, plants
11/02/2010US7824678 Antibodies against cancer antigen TMEFF2 and uses thereof
11/02/2010US7824677 inhibiting blood coagulation mediated by factor X binding to tissue factor; provide superior anti-coagulant activity by binding native human tissue factor with high affinity and specificity; linked covalently to a cell antigen or an effector molecule to provide complement fixing ability
11/02/2010US7824676 Immunoglobulin specific to junction-enriched and -associated proteins (JEAP) for use in identifying proteins localized at cell-to-cell junctions; fluorescence-labeled protein localization
11/02/2010US7824674 An antibody for treating Crohn's disease and ulcerative colitis, inhibit the transduction of biological activity of cytokine, B-cell differentiation factors
11/02/2010CA2596977C Pyy agonists and uses thereof
11/02/2010CA2454731C A system for antibody expression and assembly
11/02/2010CA2417432C Modified polypeptides stabilized in a desired conformation and methods for producing same
11/02/2010CA2330170C Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
11/02/2010CA2253246C Purified multimerase
11/02/2010CA2181394C Ctla4 mutant molecules and uses thereof
10/2010
10/28/2010WO2010124188A1 Anti-human ror1 antibodies
10/28/2010WO2010124180A1 Phenylalanine hydroxylase fusion protein and methods for treating phenylketonuria
10/28/2010WO2010124113A1 Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
10/28/2010WO2010124018A1 FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES
10/28/2010WO2010123874A1 Antibodies specific to cadherin-17
10/28/2010WO2010123519A1 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
10/28/2010WO2010123080A1 Method for producing soluble sr-a protein and evaluation method using same
10/28/2010WO2010123013A1 Tag peptide having protease recognition sequence and utilization of same
10/28/2010WO2010123012A1 Antibody containing igg2 having amino acid mutation introduced therein
10/28/2010WO2010122846A1 Cocktail antibody for determining histological type of carcinoma, determination kit and determination method
10/28/2010WO2010122234A1 Antibodies directed to tra antigens, and methods of production, screening and analysis of said antibodies, as well as methods of analysis of stem cells and cancer cell
10/28/2010WO2010122232A1 An antibody-glycan complex targeting the disialyl core ii and sialyl lewis x structures, and uses thereof involving analysis of stem cells or cancer cells
10/28/2010WO2010122181A1 Oligomeric proteins and the uses thereof
10/28/2010WO2010122148A1 An improved antibody domain and antibody fragments and antibodies based thereon
10/28/2010WO2010122090A1 Fgfr1c antibody combinations
10/28/2010WO2010121923A1 Rspondin-3 inhibition in bone disorders
10/28/2010WO2010121766A1 Antibody fusion proteins with modified fcrn binding sites
10/28/2010WO2010077473A3 Monoclonal antibodies that react with the capsule of bacillus anthracis
10/28/2010WO2010052344A3 Antibodies to modified human igf-1/e peptides
10/28/2010WO2010027499A3 Methods, compositions and vaccines relating to neisseria meningitidis antibodies
10/28/2010US20100275284 Inhibitor of apoptosis proteins and nucleic acids and methods for making and using them
10/28/2010US20100275280 Method for identifying, expanding and removing adult stem cells and cancer stem cells
10/28/2010US20100273995 Polynucleotides and their use for detecting resistance to streptogramin a or to streptogramin B and related compounds
10/28/2010US20100273992 Method for the production of an immunostimulating mucin (muc1)
10/28/2010US20100273991 Method of covalently modifying proteins with organic molecules to prevent aggregation
10/28/2010US20100273990 Notch-based fusion proteins and uses thereof
10/28/2010US20100273989 Angiotensin converting enzyme homolog and uses therefor
10/28/2010US20100273988 Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
10/28/2010US20100273981 Use of Silintaphin for the Structure-Directed Fabrication of (Nano)Composite Materials in Medicine and (Nano)Technology
10/28/2010US20100273862 Phosphatases which activate map kinase pathways
10/28/2010US20100273843 Heterocyclic self-immolative linkers and conjugates
10/28/2010US20100273705 Method for inhibiting "Melanoma Inhibitory Activity" MIA
10/28/2010US20100273660 ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS
10/28/2010US20100273274 Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans
10/28/2010US20100273257 Apo-2DcR
10/28/2010US20100273234 Process for obtaining bioactive recombinant protein from inclusion bodies
10/28/2010US20100273233 Amyloid specific peptides and uses thereof
10/28/2010US20100273193 Triacetone Triperoxide and Diacetone Diperoxide Derivatives, Method for the Preparation and Use Thereof
10/28/2010US20100273190 Pkhdl1, a homolog of the autosomal recessive kidney disease gene
10/28/2010US20100273188 Serum Prolactin Binding Protein in Epithelial Carcinoma
10/28/2010US20100273187 Antibodies against delta-5 desaturase and uses thereof
10/28/2010US20100273182 Truncated Proteins As Cancer Markers
10/28/2010US20100273161 Detection of bacteria belonging to the genus campylobacter by targeting cytolethal distending toxin
10/28/2010US20100273155 Determination of quality features in agricultural and horticultural crops
10/28/2010US20100273145 Assay method utilizing polynucleotide sequences
10/28/2010US20100272746 Lipoparticle comprising a protein and methods of making and using the same
10/28/2010US20100272742 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
10/28/2010US20100272740 Micro- and nanoscale devices for delivery of active fibronolytic agents
10/28/2010US20100272739 Modulation of Gamma-Delta T Cells to Regulate Airway Hyperresponsiveness
10/28/2010US20100272738 Anti-ox40l antibodies and methods using same
10/28/2010US20100272737 Novel Peptides and Protein and Uses Thereof
10/28/2010US20100272735 METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES
10/28/2010US20100272734 Compositions and methods for increasing muscle growth
10/28/2010US20100272733 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)
10/28/2010US20100272732 Emp2 antibodies and their therapeutic uses
10/28/2010US20100272731 Engineered anti-il-23p19 antibodies
10/28/2010US20100272730 Antigenic GM-CSF Peptides And Antibodies To GM-CSF
10/28/2010US20100272729 Mammalian tumor susceptibility gene products and their uses
10/28/2010US20100272728 Mammalian tumor susceptibility gene products and their uses
10/28/2010US20100272727 Compound for controlling appetite
10/28/2010US20100272726 Assays, methods and means
10/28/2010US20100272725 Neisserial antigens
10/28/2010US20100272724 Binding molecules capable of neutralizing rabies virus and uses thereof
10/28/2010US20100272723 Optimized Antibodies that Target CD19
10/28/2010US20100272720 Antibody Fusion Proteins with a Modified FcRn Binding Site
10/28/2010US20100272718 Antibodies Against Human NKG2D and Uses Thereof
10/28/2010US20100272716 Antibodies to VLA-1
10/28/2010US20100272715 Variable antibodies
10/28/2010US20100272714 Anti-ADDL Antibodies and Uses Thereof
10/28/2010US20100272640 Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor
10/28/2010US20100272639 Polysaccharide nanoparticles
10/28/2010CA2759733A1 Anti-human ror1 antibodies
10/28/2010CA2759538A1 Antibodies specific to cadherin-17
10/28/2010CA2759506A1 Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
10/28/2010CA2759333A1 Antibody fusion proteins with modified fcrn binding sites
10/28/2010CA2759325A1 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
10/28/2010CA2759146A1 Antibody containing igg2 having amino acid mutation introduced therein
10/28/2010CA2758842A1 Fgfr1c antibody combinations
10/28/2010CA2758524A1 Fragmentation resistant igg1 fc-conjugates
10/27/2010EP2243837A1 Carotene synthase gene and uses therefor
10/27/2010EP2243835A2 Antibodies against insulin-like growth factor I receptor and uses thereof
10/27/2010EP2243829A1 Improved humanized anti-human 9-integrin antibody
10/27/2010EP2243789A1 P.gingivalis antigenic composition
1 ... 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 ... 1494